Professor Jun Zhang’s research interests focus on the virology, immunology and epidemiology of human pathogens. As one of the leading scientists, he is deeply involved in the innovation and translation of hepatitis E vaccine, HPV vaccine, COVID-19 vaccine and many immunologic diagnostic reagents against infectious pathogens. Among them, Hepatitis E vaccine (Hecolin) and HPV 16/18 bivalent vaccine (Cecolin) had been launched in China; the nine-valent HPV vaccine are under Phase III clinical trial. He had published > 100 papers in peer reviewed journals.